Cargando…
Remote ischemic conditioning in septic shock (RECO-Sepsis): study protocol for a randomized controlled trial
BACKGROUND: Septic shock is a major public health problem that is associated with up to 50% mortality. Unfavorable outcomes are mainly attributed to multiple organ failure (MOF) resulting from an uncontrolled inflammatory response and ischemia-reperfusion processes. REmote ischemic COnditioning (REC...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532140/ https://www.ncbi.nlm.nih.gov/pubmed/31118101 http://dx.doi.org/10.1186/s13063-019-3406-4 |
_version_ | 1783420950503489536 |
---|---|
author | Cour, Martin Buisson, Marielle Klouche, Kada Bouzgarrou, Radhia Schwebel, Carole Quenot, Jean-Pierre Zeni, Fabrice Beuret, Pascal Ovize, Michel Argaud, Laurent |
author_facet | Cour, Martin Buisson, Marielle Klouche, Kada Bouzgarrou, Radhia Schwebel, Carole Quenot, Jean-Pierre Zeni, Fabrice Beuret, Pascal Ovize, Michel Argaud, Laurent |
author_sort | Cour, Martin |
collection | PubMed |
description | BACKGROUND: Septic shock is a major public health problem that is associated with up to 50% mortality. Unfavorable outcomes are mainly attributed to multiple organ failure (MOF) resulting from an uncontrolled inflammatory response and ischemia-reperfusion processes. REmote ischemic COnditioning (RECO) is a promising intervention to prevent ischemia-reperfusion injury. We hypothesize that RECO would reduce the severity of septic shock-induced MOF. METHODS/DESIGN: RECO in septic shock patients (RECO-Sepsis study) is an ongoing, prospective, multicenter, randomized, open-label trial, testing whether RECO, as an adjuvant therapy to conventional treatment in septic shock, decreases the severity of MOF as assessed by the Sequential Organ Failure Assessment (SOFA) score. Adult patients admitted to an intensive care unit with documented or suspected infection, lactatemia > 2 mmol/l, and treated with norepinephrine for less than 12 h are potentially eligible for the study. Non-inclusion criteria are: having expressed the wish not to be resuscitated, contraindication for the use of a brachial cuff on both arms, intercurrent disease with an expected life expectancy of less than 24 h, cardiac arrest, and pregnant or breastfeeding women. After enrollment, patients are randomized (n = 180) 1:1 to receive RECO or no adjunctive intervention. RECO consists of four cycles of cuff inflation to 200 mmHg for 5 min and then deflation to 0 mmHg for another 5 min. RECO is performed at inclusion and repeated 12 and 24 h later. The primary endpoint is the mean daily SOFA score up to day 4 after inclusion. Secondary outcomes include the need for organ support, hospital length of stay, and 90-day mortality. DISCUSSION: Results of this proof-of-concept trial should provide information on the efficacy of RECO in patients with septic shock. TRIAL REGISTRATION: ClinicalTrials.gov, ID: identifier: NCT03201575. Registered on 28 June 2017. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3406-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6532140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65321402019-05-28 Remote ischemic conditioning in septic shock (RECO-Sepsis): study protocol for a randomized controlled trial Cour, Martin Buisson, Marielle Klouche, Kada Bouzgarrou, Radhia Schwebel, Carole Quenot, Jean-Pierre Zeni, Fabrice Beuret, Pascal Ovize, Michel Argaud, Laurent Trials Study Protocol BACKGROUND: Septic shock is a major public health problem that is associated with up to 50% mortality. Unfavorable outcomes are mainly attributed to multiple organ failure (MOF) resulting from an uncontrolled inflammatory response and ischemia-reperfusion processes. REmote ischemic COnditioning (RECO) is a promising intervention to prevent ischemia-reperfusion injury. We hypothesize that RECO would reduce the severity of septic shock-induced MOF. METHODS/DESIGN: RECO in septic shock patients (RECO-Sepsis study) is an ongoing, prospective, multicenter, randomized, open-label trial, testing whether RECO, as an adjuvant therapy to conventional treatment in septic shock, decreases the severity of MOF as assessed by the Sequential Organ Failure Assessment (SOFA) score. Adult patients admitted to an intensive care unit with documented or suspected infection, lactatemia > 2 mmol/l, and treated with norepinephrine for less than 12 h are potentially eligible for the study. Non-inclusion criteria are: having expressed the wish not to be resuscitated, contraindication for the use of a brachial cuff on both arms, intercurrent disease with an expected life expectancy of less than 24 h, cardiac arrest, and pregnant or breastfeeding women. After enrollment, patients are randomized (n = 180) 1:1 to receive RECO or no adjunctive intervention. RECO consists of four cycles of cuff inflation to 200 mmHg for 5 min and then deflation to 0 mmHg for another 5 min. RECO is performed at inclusion and repeated 12 and 24 h later. The primary endpoint is the mean daily SOFA score up to day 4 after inclusion. Secondary outcomes include the need for organ support, hospital length of stay, and 90-day mortality. DISCUSSION: Results of this proof-of-concept trial should provide information on the efficacy of RECO in patients with septic shock. TRIAL REGISTRATION: ClinicalTrials.gov, ID: identifier: NCT03201575. Registered on 28 June 2017. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3406-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-22 /pmc/articles/PMC6532140/ /pubmed/31118101 http://dx.doi.org/10.1186/s13063-019-3406-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Cour, Martin Buisson, Marielle Klouche, Kada Bouzgarrou, Radhia Schwebel, Carole Quenot, Jean-Pierre Zeni, Fabrice Beuret, Pascal Ovize, Michel Argaud, Laurent Remote ischemic conditioning in septic shock (RECO-Sepsis): study protocol for a randomized controlled trial |
title | Remote ischemic conditioning in septic shock (RECO-Sepsis): study protocol for a randomized controlled trial |
title_full | Remote ischemic conditioning in septic shock (RECO-Sepsis): study protocol for a randomized controlled trial |
title_fullStr | Remote ischemic conditioning in septic shock (RECO-Sepsis): study protocol for a randomized controlled trial |
title_full_unstemmed | Remote ischemic conditioning in septic shock (RECO-Sepsis): study protocol for a randomized controlled trial |
title_short | Remote ischemic conditioning in septic shock (RECO-Sepsis): study protocol for a randomized controlled trial |
title_sort | remote ischemic conditioning in septic shock (reco-sepsis): study protocol for a randomized controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532140/ https://www.ncbi.nlm.nih.gov/pubmed/31118101 http://dx.doi.org/10.1186/s13063-019-3406-4 |
work_keys_str_mv | AT courmartin remoteischemicconditioninginsepticshockrecosepsisstudyprotocolforarandomizedcontrolledtrial AT buissonmarielle remoteischemicconditioninginsepticshockrecosepsisstudyprotocolforarandomizedcontrolledtrial AT klouchekada remoteischemicconditioninginsepticshockrecosepsisstudyprotocolforarandomizedcontrolledtrial AT bouzgarrouradhia remoteischemicconditioninginsepticshockrecosepsisstudyprotocolforarandomizedcontrolledtrial AT schwebelcarole remoteischemicconditioninginsepticshockrecosepsisstudyprotocolforarandomizedcontrolledtrial AT quenotjeanpierre remoteischemicconditioninginsepticshockrecosepsisstudyprotocolforarandomizedcontrolledtrial AT zenifabrice remoteischemicconditioninginsepticshockrecosepsisstudyprotocolforarandomizedcontrolledtrial AT beuretpascal remoteischemicconditioninginsepticshockrecosepsisstudyprotocolforarandomizedcontrolledtrial AT ovizemichel remoteischemicconditioninginsepticshockrecosepsisstudyprotocolforarandomizedcontrolledtrial AT argaudlaurent remoteischemicconditioninginsepticshockrecosepsisstudyprotocolforarandomizedcontrolledtrial |